Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells

摘要: // Ling Dong 1, * , Huijuan Lv Wei Li 1 Zheng Song Lanfang Shiyong Zhou Lihua Qiu Zhengzi Qian Xianming Liu Lixia Feng Bin Meng 2 Kai Fu 3 Xi Wang 4 Qiang Pan-Hammarstrom 5 Ping 6 Xianhuo Huilai Zhang Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute Hospital, National Clinical Research Cancer, Key Laboratory Prevention Therapy, Tianjin, China Pathology, Pathology Microbiology Internal Medicine, Nebraska Center, Omaha, NE, USA Cellular Biology, School Basic Sciences, University, Immunology, Karolinska Institutet at Hospital Huddinge, Stockholm, Sweden Radiotherapy, These authors have contributed equally to this work Correspondence to: Zhang, email: zhlwgq@126.com Wang, tjzlyy_xianhuow@163.com Keywords: PD-1, PD-L1, p-AKT, AKT/mTOR signaling, DLBCL Received: January 06, 2016     Accepted: March 31, Published: April 27, 2016 ABSTRACT Programmed death-1 (PD-1) /programmed death-ligand (PD-L1) engagement usually leads diminished antitumor T-cell responses, which mediates the immune escape tumor cells. However, little is known whether PD-1/PD-L1 could directly activates intracellular oncogenic signaling pathways in The purpose study investigate be activated by during malignant progression diffuse large B-cell lymphoma (DLBCL). Detection expression PD-L1 p-AKT immunohistochemistry (IHC) showed that both proteins were overexpressed 54% 48% cases, respectively. Spearman test was correlated with (R=0.244, χ =5.962; P =0.017) also clinic-pathological characteristics. In addition, survival analysis patients who co-expressed had significantly poorer outcome than single positive or negative ( <0.05). vitro, total membrane (mPD-L1) five cell lines western blot flow cytometry. We observed pathway cells after stimulated human recombination PD-1/Fc. Taken together, these results suggested combination antibodies inhibitor might a promising novel therapeutic approach future.